Citius Pharmaceuticals (CTXR) Other Working Capital Changes (2019 - 2026)
Citius Pharmaceuticals' (CTXR) quarterly Other Working Capital Changes came in at -$21484.0 in Q1 2026, up 63.87% YoY from -$13110.0 in Q1 2025, and down 231.22% on a QoQ basis from $16373.0 in Q4 2025.
Citius Pharmaceuticals (CTXR) Other Working Capital Changes (2019 - 2026) Analysis & Trends
Citius Pharmaceuticals (CTXR) has 8 years of Other Working Capital Changes data on file, last reported at -$21484.0 in Q1 2026.
- Quarterly Other Working Capital Changes rose 63.87% year-over-year to -$21484.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$123633.0 (up 46.18% YoY) and the FY2025 annual result came in at -$236289.0, down 8.2% from the prior year.
- Other Working Capital Changes declined to -$21484.0 in Q1 2026, from $16373.0 in the prior quarter.
- In the past five years, Other Working Capital Changes ranged from a high of $16373.0 in Q4 2025 to a low of -$68378.0 in Q3 2025.
- A 5-year average of -$46547.5 and a median of -$50144.0 in 2025 frame the typical range for Other Working Capital Changes.
- The widest YoY moves for Other Working Capital Changes: up 128.09% in 2025, down 19.65% in 2025.
- Tracing CTXR's Other Working Capital Changes over 5 years: stood at -$47488.0 in 2022, then retreated by 10.92% to -$52676.0 in 2023, then retreated by 10.67% to -$58296.0 in 2024, then soared by 128.09% to $16373.0 in 2025, then sank by 231.22% to -$21484.0 in 2026.
- The last three Other Working Capital Changes figures came in at -$21484.0 (Q1 2026), $16373.0 (Q4 2025), and -$68378.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.41 Bn | 131.56 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.14 Bn | 78.15 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.52 Bn | 60.34 Bn | 1.37 Bn |
| 4 | Moderna | 58.21 Bn | 53.07 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.95 Bn | 9.56 Bn | 668.28 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.46 Bn | - |
| 10 | Citius Pharmaceuticals | 15.86 Mn | 15.86 Mn | 1.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -21,484.00 |
| Mar 31, 2026 | -21,484.00 |
| Mar 31, 2026 | -21,484.00 |
| Dec 31, 2025 | 16,373.00 |
| Dec 31, 2025 | 16,373.00 |
| Dec 31, 2025 | 16,373.00 |
| Sep 30, 2025 | -68,378.00 |
| Sep 30, 2025 | -68,378.00 |
| Sep 30, 2025 | -68,378.00 |
| Jun 30, 2025 | -50,144.00 |
| Jun 30, 2025 | -50,144.00 |
| Jun 30, 2025 | -50,144.00 |
| Mar 31, 2025 | -59,471.00 |
| Mar 31, 2025 | -59,471.00 |
| Mar 31, 2025 | -59,471.00 |
| Dec 31, 2024 | -58,296.00 |
| Dec 31, 2024 | -58,296.00 |
| Dec 31, 2024 | -58,296.00 |
| Sep 30, 2024 | -57,146.00 |
| Sep 30, 2024 | -57,146.00 |